NASDAQ:VNDA Vanda Pharmaceuticals (VNDA) Stock Forecast, Price & News $4.51 +0.05 (+1.12%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$4.28▼$4.5750-Day Range$4.28▼$6.5352-Week Range$4.15▼$11.04Volume1.21 million shsAverage Volume2.22 million shsMarket Capitalization$259.37 millionP/E Ratio16.70Dividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Vanda Pharmaceuticals MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish5.04% of Float Sold ShortDividend StrengthN/ASustainability-1.77Upright™ Environmental ScoreNews Sentiment0.00Based on 2 Articles This WeekInsider TradingSelling Shares$75,009 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.94 out of 5 starsMedical Sector645th out of 966 stocksPharmaceutical Preparations Industry297th out of 446 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Vanda Pharmaceuticals. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.04% of the float of Vanda Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVanda Pharmaceuticals has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vanda Pharmaceuticals has recently increased by 5.26%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVanda Pharmaceuticals does not currently pay a dividend.Dividend GrowthVanda Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVanda Pharmaceuticals has received a 61.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Tasimelteon", "Antipsychotics", and "Clinical research services for psychotic disorders" products. See details.Environmental SustainabilityThe Environmental Impact score for Vanda Pharmaceuticals is -1.77. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Vanda Pharmaceuticals this week, compared to 1 article on an average week.Search Interest4 people have searched for VNDA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows4 people have added Vanda Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vanda Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $75,009.00 in company stock.Percentage Held by InsidersOnly 7.70% of the stock of Vanda Pharmaceuticals is held by insiders.Percentage Held by Institutions97.92% of the stock of Vanda Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Vanda Pharmaceuticals is 16.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 123.09.Price to Earnings Ratio vs. SectorThe P/E ratio of Vanda Pharmaceuticals is 16.70, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 131.05.Price to Book Value per Share RatioVanda Pharmaceuticals has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Vanda Pharmaceuticals (NASDAQ:VNDA) StockVanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.Read More VNDA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VNDA Stock News HeadlinesSeptember 22, 2023 | stocknews.comBionano Genomics (BNGO) Challengers: 3 Biotech Innovators to Buy InsteadSeptember 5, 2023 | finance.yahoo.comWhy Shares of Vanda Pharmaceuticals Are Dropping on TuesdaySeptember 23, 2023 | Stansberry Research (Ad)New gold-backed currency could kill the DollarRumors are circulating of a new currency that will be backed by gold. A huge story, if true. And while it’s impossible to know how it will pan out, there’s one important move you should make right now, before this happens. It’s the best way to protect your wealth today. Because if you’re not careful, YOU could be the one who pays the priceSeptember 1, 2023 | finance.yahoo.com5 Biotech Stocks to Buy as New Drug Approvals Drive Industry ProspectsSeptember 1, 2023 | finance.yahoo.comAfter Plunging -7.98% in 4 Weeks, Here's Why the Trend Might Reverse for Vanda (VNDA)August 17, 2023 | fool.comVanda Pharmaceuticals (NASDAQ: VNDA)August 1, 2023 | finance.yahoo.comEarnings growth of 9.4% over 5 years hasn't been enough to translate into positive returns for Vanda Pharmaceuticals (NASDAQ:VNDA) shareholdersJuly 28, 2023 | finanznachrichten.deVanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Reports Second Quarter 2023 Financial ResultsSeptember 23, 2023 | Stansberry Research (Ad)New gold-backed currency could kill the DollarRumors are circulating of a new currency that will be backed by gold. A huge story, if true. And while it’s impossible to know how it will pan out, there’s one important move you should make right now, before this happens. It’s the best way to protect your wealth today. Because if you’re not careful, YOU could be the one who pays the priceJuly 28, 2023 | finance.yahoo.comVanda Pharmaceuticals Reports Second Quarter 2023 Financial ResultsJuly 28, 2023 | finance.yahoo.comQ2 2023 Vanda Pharmaceuticals Inc Earnings CallJuly 27, 2023 | markets.businessinsider.comWhat Wall Street expects from Vanda Pharmaceuticals's earningsJuly 25, 2023 | thestreet.comVanda's Hetlioz Is Starting to Sell -- Slowly -- After Bumbling Through the PipelineJuly 20, 2023 | finance.yahoo.comVanda Pharmaceuticals to Announce Second Quarter 2023 Financial Results on July 27, 2023June 5, 2023 | finance.yahoo.comVanda Pharmaceuticals Announces Participation in the Jefferies 2023 Global Healthcare ConferenceJune 2, 2023 | msn.comVanda gains on FDA orphan drug designation for nerve disorder candidateJune 1, 2023 | finance.yahoo.comVanda Pharmaceuticals Announces Orphan Drug Designation Granted for VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2SJune 1, 2023 | finance.yahoo.comVanda Pharmaceuticals Announces Presentations at SLEEP 2023May 30, 2023 | bizjournals.comVanda Pharmaceuticals eyeing ‘path forward’ for motion sickness treatmentMay 25, 2023 | finance.yahoo.comA Sea Change in Motion Sickness Therapy: Vanda Pharmaceuticals' Tradipitant Shows Promising Data in Real-world TestMay 25, 2023 | finance.yahoo.comVanda Pharmaceuticals Reports Results from a Phase III study of Tradipitant in Motion SicknessMay 24, 2023 | entrepreneur.com4 Best Biotech Stocks According to POWR RatingsMay 10, 2023 | finance.yahoo.comVanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA AppealMay 4, 2023 | finance.yahoo.comVanda Pharmaceuticals Announces Presentations at DDW 2023May 4, 2023 | finance.yahoo.comQ1 2023 Vanda Pharmaceuticals Inc Earnings CallMay 3, 2023 | reuters.comVanda Pharmaceuticals sues US over drug-trade secretsMay 3, 2023 | finance.yahoo.comVanda Pharmaceuticals Reports First Quarter 2023 Financial ResultsSee More Headlines Receive VNDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address VNDA Company Calendar Last Earnings7/27/2023Today9/23/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:VNDA CUSIP92165910 CIK1347178 Webwww.vandapharma.com Phone(202) 734-3400Fax202-296-1450Employees290Year Founded2002Profitability EPS (Most Recent Fiscal Year)$0.27 Trailing P/E Ratio16.70 Forward P/E RatioN/A P/E GrowthN/ANet Income$6.28 million Net Margins6.25% Pretax Margin9.73% Return on Equity2.81% Return on Assets2.34% Debt Debt-to-Equity RatioN/A Current Ratio6.10 Quick Ratio6.09 Sales & Book Value Annual Sales$254.38 million Price / Sales1.02 Cash Flow$0.11 per share Price / Cash Flow40.07 Book Value$9.32 per share Price / Book0.48Miscellaneous Outstanding Shares57,510,000Free Float53,081,000Market Cap$259.37 million OptionableOptionable Beta0.70 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Mihael H. Polymeropoulos M.D. (Age 63)Founder, Pres, CEO & Chairman of The Board Comp: $1.51MMr. Kevin Patrick Moran (Age 39)Sr. VP, CFO & Treasurer Comp: $660.22kMr. Timothy Williams (Age 47)Sr. VP, Gen. Counsel & Sec. Comp: $724.38kMr. Joakim Wijkstrom (Age 57)Sr. VP & Chief Marketing Officer Comp: $836.36kMr. Gunther Birznieks (Age 53)Sr. VP of Bus. Devel. Comp: $690.83kMr. Scott L. HowellChief People OfficerMs. Elizabeth Van EveryHead of Corp. AffairsMore ExecutivesKey CompetitorsVerastemNASDAQ:VSTMLexicon PharmaceuticalsNASDAQ:LXRXEmergent BioSolutionsNYSE:EBSRigel PharmaceuticalsNASDAQ:RIGLXOMANASDAQ:XOMAView All CompetitorsInsiders & InstitutionsBarclays PLCBought 24,771 shares on 9/21/2023Ownership: 0.217%Virginia Retirement Systems ET ALBought 52,400 shares on 8/22/2023Ownership: 0.091%Joakim WijkstromSold 3,724 sharesTotal: $21,748.16 ($5.84/share)Nuveen Asset Management LLCSold 193,685 shares on 8/16/2023Ownership: 0.696%State of Tennessee Treasury DepartmentBought 3,559 shares on 8/15/2023Ownership: 0.064%View All Insider TransactionsView All Institutional Transactions VNDA Stock - Frequently Asked Questions How have VNDA shares performed in 2023? Vanda Pharmaceuticals' stock was trading at $7.39 at the start of the year. Since then, VNDA stock has decreased by 39.0% and is now trading at $4.51. View the best growth stocks for 2023 here. When is Vanda Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our VNDA earnings forecast. How were Vanda Pharmaceuticals' earnings last quarter? Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) issued its quarterly earnings results on Thursday, July, 27th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.16. The biopharmaceutical company earned $46.06 million during the quarter, compared to analyst estimates of $49 million. Vanda Pharmaceuticals had a net margin of 6.25% and a trailing twelve-month return on equity of 2.81%. What ETFs hold Vanda Pharmaceuticals' stock? ETFs with the largest weight of Vanda Pharmaceuticals (NASDAQ:VNDA) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Horizon Kinetics Medical ETF (MEDX), iShares Neuroscience and Healthcare ETF (IBRN), iShares U.S. Pharmaceuticals ETF (IHE), What is Mihael H. Polymeropoulos' approval rating as Vanda Pharmaceuticals' CEO? 12 employees have rated Vanda Pharmaceuticals Chief Executive Officer Mihael H. Polymeropoulos on Glassdoor.com. Mihael H. Polymeropoulos has an approval rating of 24% among the company's employees. This puts Mihael H. Polymeropoulos in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Vanda Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Array Technologies (ARRY), Micron Technology (MU) and Novavax (NVAX). What is Vanda Pharmaceuticals' stock symbol? Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA." Who are Vanda Pharmaceuticals' major shareholders? Vanda Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (18.80%), State Street Corp (7.10%), Renaissance Technologies LLC (5.41%), Goldman Sachs Group Inc. (3.66%), Dimensional Fund Advisors LP (3.39%) and Hotchkis & Wiley Capital Management LLC (2.18%). Insiders that own company stock include Aranthan Jones II, Gunther Birznieks, Joakim Wijkstrom, Kevin Patrick Moran, Melissa Young, Mihael Hristos Polymeropoulos, Phaedra Chrousos, Richard W Dugan, Stephen Ray Mitchell, Thomas Watkins and Timothy Williams. View institutional ownership trends. How do I buy shares of Vanda Pharmaceuticals? Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Vanda Pharmaceuticals' stock price today? One share of VNDA stock can currently be purchased for approximately $4.51. How much money does Vanda Pharmaceuticals make? Vanda Pharmaceuticals (NASDAQ:VNDA) has a market capitalization of $259.37 million and generates $254.38 million in revenue each year. The biopharmaceutical company earns $6.28 million in net income (profit) each year or $0.27 on an earnings per share basis. How many employees does Vanda Pharmaceuticals have? The company employs 290 workers across the globe. How can I contact Vanda Pharmaceuticals? Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. The official website for the company is www.vandapharma.com. The biopharmaceutical company can be reached via phone at (202) 734-3400, via email at pr@vandapharma.com, or via fax at 202-296-1450. This page (NASDAQ:VNDA) was last updated on 9/23/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.